SCHEMBL756843

SCHEMBL756843

CC1(C)Oc2cc(N)ccc2N(c2ccc(F)cc2)C1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 6/20 0.63
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
AR P10275 1/20 0.40
SLC9A1 P19634 1/20 0.38
PGR P06401 1/20 0.37
HTT P42858 2/20 0.36
MGLL Q99685 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PIK3CD O00329 1/20 0.35
HSD11B1 P28845 1/20 0.35
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL759723 0.87 NR3C2 (0.49) NR3C2ARSLC9A1PIK3CD
SCHEMBL756030 0.86 NR3C2 (0.47) NR3C2CACNA1BAPBA1SLC9A1PGR
SCHEMBL16978177 0.85 NR3C2 (0.65) NR3C2CACNA1BAPBA1ARSLC9A1
SCHEMBL758023 0.85 NR3C2 (0.47) NR3C2ARSLC9A1NPC1RAB9A
SCHEMBL754584 0.83 NR3C2 (0.46) NR3C2ARSLC9A1HTTALDH1A1
SCHEMBL753914 0.83 NR3C2 (0.46) NR3C2CACNA1BAPBA1PGRHTT
SCHEMBL753825 0.83 NR3C2 (0.57) NR3C2CACNA1BAPBA1ARSLC9A1
SCHEMBL756162 0.83 NR3C2 (0.46) NR3C2CACNA1BAPBA1PGRALDH1A1
SCHEMBL755148 0.82 NR3C2 (0.45) NR3C2ARSLC9A1ALDH1A1PIK3CD
SCHEMBL2267353 0.82 NR3C2 (0.56) NR3C2CACNA1BAPBA1ARSLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2883870-B1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2018-10-24 EP disclosed
EP-3112354-B1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2018-07-25 EP disclosed
EP-3112354-B1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2018-07-25 EP disclosed
US-9751846-B2 Method for producing 1,4-benzoxazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-09-05 US disclosed
US-9751846-B2 Method for producing 1,4-benzoxazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-09-05 US disclosed
US-9751846-B2 Method for producing 1,4-benzoxazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-09-05 US disclosed
EP-3112354-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2017-01-04 EP disclosed
EP-3112354-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2017-01-04 EP disclosed
US-20160362385-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-12-15 US disclosed
US-20160362385-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-12-15 US disclosed
US-20150218113-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-06 US disclosed
US-20150218113-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-06 US disclosed
EP-2883870-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-06-17 EP disclosed
EP-2883870-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-06-17 EP disclosed
US-8188073-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
EP-1984345-B9 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 EP disclosed
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS IIJIMA TORU 2011-10-13 US disclosed
EP-1984345-B1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORP (JP) 2011-08-31 EP disclosed
US-7998956-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-16 US disclosed
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218113-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND BRSK1, BRSK2, MSMO1 NR3C2 1315/4885CACNA1B 689/4885APBA1 1882/4885
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents NR3C2, MC2R, NR3C1 NR3C2 1/4885CACNA1B 722/4885APBA1 3631/4885
US-20160362385-A1 METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND BRSK1, BRSK2, MSMO1 NR3C2 1315/4885CACNA1B 689/4885APBA1 1882/4885
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS NR3C2, MC2R, NR3C1 NR3C2 1/4885CACNA1B 722/4885APBA1 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.